84
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Commensal gut microflora and dietary fiber protect against colonic inflammation and colon cancer through unknown targets. Butyrate, a bacterial product from fermentation of dietary fiber in the colon, has been implicated in this process. GPR109A (encoded by Niacr1) is a receptor for butyrate in the colon. GPR109A is also a receptor for niacin, which is also produced by gut microbiota and suppresses intestinal inflammation. Here we showed that Gpr109a signaling promoted anti-inflammatory properties in colonic macrophages and dendritic cells and enabled them to induce differentiation of Treg cells and IL-10-producing T cells. Moreover, Gpr109a was essential for butyrate-mediated induction of IL-18 in colonic epithelium. Consequently, Niacr1(-/-) mice were susceptible to development of colonic inflammation and colon cancer. Niacin, a pharmacological Gpr109a agonist, suppressed colitis and colon cancer in a Gpr109a-dependent manner. Thus, Gpr10a has an essential role in mediating the beneficial effects of gut microbiota and dietary fiber in colon.

          Related collections

          Author and article information

          Journal
          Immunity
          Immunity
          Elsevier BV
          1097-4180
          1074-7613
          Jan 16 2014
          : 40
          : 1
          Affiliations
          [1 ] Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA; Cancer Research Center, Georgia Regents University, Augusta, GA 30912, USA. Electronic address: nasingh@gru.edu.
          [2 ] Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA.
          [3 ] Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA; Cancer Research Center, Georgia Regents University, Augusta, GA 30912, USA.
          [4 ] Cancer Research Center, Georgia Regents University, Augusta, GA 30912, USA.
          [5 ] Cancer Research Center, Georgia Regents University, Augusta, GA 30912, USA; Department of Pediatrics, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA.
          [6 ] Department of Pathology, Charlie Norwood Veterans Administration Medical Center, Augusta, GA 30904, USA.
          [7 ] Department of Pharmacology, Max-Planck-Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany.
          [8 ] Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA; Cancer Research Center, Georgia Regents University, Augusta, GA 30912, USA. Electronic address: vganapat@gru.edu.
          Article
          S1074-7613(13)00564-5 NIHMS643704
          10.1016/j.immuni.2013.12.007
          4305274
          24412617
          412c40e9-0fea-4318-aca5-bf4e102bdf13
          Copyright © 2014 Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article